Skip to main content
Ensol Biosciences Inc. logo

Ensol Biosciences Inc. — Investor Relations & Filings

Ticker · 140610 ISIN · KR7140610007 KO Manufacturing
Filings indexed 257 across all filing types
Latest filing 2018-10-12 Investor Presentation
Country KR South Korea
Listing KO 140610

About Ensol Biosciences Inc.

https://www.ensolbio.co.kr/eng/

Ensol Biosciences Inc. is a biopharmaceutical company focused on developing innovative drugs for diseases with limited or no therapeutic alternatives. The company leverages a bio big data and AI-driven platform for its research and development activities. A core area of its technology involves Protein-Protein Interaction (PPI)-regulating short peptide drugs, which are designed for local injection to maximize therapeutic effects and minimize systemic side effects through high specificity and a short half-life in the blood. The company's pipeline targets a range of medical unmet needs, including degenerative disc disease, osteoarthritis, cancer, and neurodegenerative disorders like Alzheimer's disease. Key clinical-stage assets include E1K for osteoarthritis (preparing for Phase 3) and C1K, an anticancer combination therapy (Phase 1).

Recent filings

Filing Released Lang Actions
기업설명회(IR)개최
Investor Presentation Classification · 98% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (기업설명회). It provides details such as the date, location, target audience, and purpose of the meeting. Since it is an announcement of an event rather than the presentation materials themselves, and it is a short regulatory notice, it falls under the category of a general regulatory announcement or a report publication/event announcement. Given the specific nature of the filing as an IR event notice, it is best classified as a Regulatory Filing (RNS).
2018-10-12 Korean
기타시장안내(약명및영문명)
Regulatory Filings Classification · 95% confidence The document is a short regulatory notice regarding a change in the company's stock name (Korean and English abbreviations). It does not contain financial statements, management reports, or other substantive disclosures, but rather serves as a formal notification of a corporate administrative change. As it does not fit into specific categories like M&A, dividends, or share repurchases, it falls under the general regulatory announcement category.
2018-10-04 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.